"Pfizer's dividend payout exceeded free cash flow by $695 million in FY2025, indicating a reliance on reserves or borrowing, which is unsustainable if it continues."
"The GAAP payout ratio is above 100%, primarily due to $4.4 billion in non-cash impairment charges in Q4 2025, highlighting the gap between earnings and dividends."
"Total debt rose from $63.6 billion in 2024 to $67.4 billion in 2025, while liquid assets fell from $20.5 billion to $13.6 billion, reflecting a tighter balance sheet."
"Despite raising dividends every year since 2010, Pfizer's growth is modest at 2% to 3% annually, and past cuts during the 2009 financial crisis remain a concern."
Pfizer's dividend yield stands at 6.3%, appealing to retirement investors. However, the company paid $9.771 billion in dividends against a free cash flow of $9.076 billion in FY2025, indicating unsustainable practices. The GAAP payout ratio exceeds 100%, driven by significant non-cash impairment charges. Total debt increased to $67.4 billion while liquid assets decreased to $13.6 billion. Despite raising dividends annually since 2010, growth remains modest. Management emphasizes stability and future growth, but past dividend cuts during crises raise concerns about sustainability.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]